Potential role of pregnancy-associated plasma protein-A in human reproduction.
By radioimmunoassay, pregnancy-associated plasma protein-A (PAPP-A) was undetectable in matched follicular and luteal phase serum samples (n = 17) or in the peripheral circulation of normal males (n = 17). However, seminal plasma (91.5%), cervical mucus (100%) and pre-ovulatory follicular fluid (99.6%) were consistently PaPP-A positive. In addition to PAPP-A, four circulating protease inhibitors (PIs) were detected in pooled seminal plasma whereas pooled follicular fluid contained an additional six. Follicular concentrations of serum PIs were inversely related to molecular size. By contrast, PAPP-A formed a positive concentration gradient across the blood-reproductive tract barrier suggesting PAPP-A production within the reproductive tract. A minor proportion (1.7%) of ejaculated spermatozoa were coated with PAPP-A, as demonstrated by direct immunofluorescence. Since PAPP-A specifically inhibits leucocyte elastase, it is suggested that PAPP-A coated spermatozoa were "selected" to overcome localized phagocytic-proteolytic degradation. The physiological significance of these findings are discussed in relation to human reproduction.
D002582:Cervix Mucus / Q000032:analysis; D005260:Female; D005298:Fertility; D005455:Fluorescent Antibody Technique; D005498:Follicular Phase; D006801:Humans; D008183:Luteal Phase; D008297:Male; D011257:Pregnancy Proteins / Q000502:physiology*; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis / Q000502:physiology*; D011480:Protease Inhibitors / Q000097:blood; D012661:Semen / Q000032:analysis
D011257:Pregnancy Proteins; D011480:Protease Inhibitors; D011266:Pregnancy-Associated Plasma Protein-A